Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03307122 · ClinicalTrials.gov registry record · NA
Gastrointestinal Tolerance Evaluation of an Infant Formula
A NA study, sponsored by Société des Produits Nestlé (SPN).
- Completed
- Registry status
- NA
- Development phase
- 79
- Enrollment target
NCT03307122: Completed NA study, sponsored by Société des Produits Nestlé (SPN).
NCT03307122 is a NA study that has completed, run by Société des Produits Nestlé (SPN). The registered enrollment target is 79 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03307122, a NA study, has completed, sponsored by Société des Produits Nestlé (SPN).
- COMPLETED
- Registry status
- NA
- Development phase
- 79 participants
- Enrollment target
Study Summary
Prospective, double-blind, randomized study of 2 infant formulas.
Primary Outcome
Study personnel will administer questionnaire
Interventions
- OTHER Routine Infant Formula 1
- OTHER Routine Infant Formula 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2017-09-21 |
| Est. Completion | 2018-01-19 |
| Phase | NA |
What the finished NCT03307122 record still lists
NCT03307122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Routine Infant Formula 1 is the first listed.
NCT03307122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03307122 about?
NCT03307122 is a clinical study titled "Gastrointestinal Tolerance Evaluation of an Infant Formula". Prospective, double-blind, randomized study of 2 infant formulas.
What is the current status of trial NCT03307122?
This trial is currently completed. It is a NA study. The enrollment target is 79 participants. The study started on 2017-09-21. Estimated completion is 2018-01-19.
What interventions are being tested in trial NCT03307122?
The interventions under investigation include: Routine Infant Formula 1 (OTHER), Routine Infant Formula 2 (OTHER).
Who is sponsoring clinical trial NCT03307122?
This trial is sponsored by Société des Produits Nestlé (SPN), which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03307122's enrollment target sits among peer trials
79 1060th of 2000 higher than 941 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI